2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA
Guideline on the Management of Dyslipidemia

The National Lipid Association (“NLA”) is a collaborating organization on the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia (“Guideline”). The NLA Board of Directors must vote to “endorse” or “not endorse” the Guideline. Your vote is due December 5, 2025.

Please use the following link to vote to “endorse” or “not endorse” the Guideline:

2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia

This request is a vote on the content of the Guideline without the opportunity to make changes to the document. In order to endorse the Guideline, the NLA must receive 50% + 1 votes to “endorse”.

Members of the NLA Board of Directors are provided confidential access to an embargoed copy of the Guideline. The NLA and the members of the Board of Directors are subject to the following confidentiality and embargo requirements provided in the Memorandum of Understanding Among the American College of Cardiology Foundation, the American Heart Association, and the National Lipid Association dated September 6, 2024, limiting use of the embargoed Guideline to this vote and prohibiting distribution of embargoed Guideline:

DEFINITIONS:

1. ACCF: American College of Cardiology Foundation
2. AHA: American Heart Association
3. Collaborator: National Lipid Association (including members of the Board of Directors)
4. Confidential Information: Defined below, inclusive of the Guideline
5. Document: Guideline

CONFIDENTIALITY AND EMBARGO

1. Collaborator will not disclose any Confidential Information, as defined herein, of ACCF or AHA to any third party, or permit any third party to examine and/or make copies of any Confidential Information.
2. For the purpose of this MOU, “Confidential Information” means any software, material, data, or business, financial, operational, customer, vendor and other information disclosed by one party to the other party(ies) (the “receiving party”) and not generally known by or disclosed to the public or known to the receiving party solely by reason of the negotiation or performance of this MOU, and shall include, without limitation, the terms of this MOU. Confidential Information shall include the names of the members of the Writing Committee of the Document, the organizations involved in the development, peer review participation, all Document content, including but not limited to written text, tables, algorithms, or figures, and the exact date and time of publication (“embargo”) of the Document.
3. Each receiving party shall maintain all of the other parties’ Confidential Information in strict confidence and will protect such information with the same degree of care that such receiving party exercises with its own Confidential Information, but in no event less than a reasonable degree of care. Except as provided in this MOU, a receiving party shall not use or disclose any Confidential Information of the other parties in any manner without the express prior written consent of the disclosing party. Access to and use of any Confidential Information shall be restricted to those employees and persons within a receiving party's organization with known discretion, and with a need to use the information to perform such receiving party's obligations under this MOU. A receiving party's consultants and subcontractors may be included within the meaning of “persons within a receiving party's organization,” provided that such consultants and subcontractors have executed a non- disclosure or confidentiality agreement with provisions no less stringent than those applicable to such receiving party under this MOU, and such receiving party shall make such signed agreements available to the other parties upon request.
4. Notwithstanding anything herein to the contrary, Confidential Information shall not include information that is: (a) already known to or otherwise in the possession of a party at the time of receipt from the other party and that was not known or received as the result of violation of any obligation of confidentiality; (b) publicly available or otherwise in the public domain prior to disclosure by a party; (c) rightfully obtained by a party from any third party having a right to disclose such information without restriction and without breach of any confidentiality obligation by such third party; (d) developed by a party independent of any disclosure hereunder, as evidenced by written records; or (e) disclosed pursuant to the order of a court or administrative body of competent jurisdiction or a government agency, provided that the party receiving such order shall notify the other prior to such disclosure and shall cooperate with the other party in the event such party elects to legally contest, request confidential treatment, or otherwise avoid such disclosure.